initial public offerings (IPOs) trading on American exchanges

Friday, June 11, 2021

Onion Global (OG) began trading on the NYSE on Fri 7 May 21

Onion Global is a Chinese e-commerce platform, a next-generation lifestyle brand platform that incubates, markets and distributes the world’s fresh, fashionable and future brands to young people, with a unique and innovative business model that leverages key opinion consumers (KOC) representing a total of nearly 700,000 social media accounts.
 
  • Sector(s): Technology
  • Industry: Software—Application
  • Full Time Employees: 796
  • Incorporated in 2009 
  • HQ in Guangzhou, China.
  • http://www.msyc.com
 

Tuesday, June 8, 2021

CarLotz (LOTZ) began trading on the Nasdaq on Fri 22 Jan 21

 CarLotz, Inc. operates as a consignment-to-retail used consignment store.
  • Sector(s): Consumer Cyclical
  • Industry: Auto & Truck Dealerships
  • Full Time Employees: 166
  • 8 locations and online sales
  • Headquartered in Richmond, Virginia
  • http://www.carlotz.com
Went public through a merger with a Nasdaq-listed special purpose acquisition (SPAC) Acamar Partners Acquisition Corp., a Miami, Florida-based SPAC that was formed in 2018 and went public with a $300 million IPO in 2019.  Acamar Partners was led by private equity investors Juan Carlos Torres Carretero and Luis Ignacio Solorzano Aizpuru.

CarLotz was the third major U.S. online car seller to go public this past year after Vroom (VRM) and Shift Technologies Inc (SFT).



Online sales only account for around 1% of the roughly $840 billion Americans spend annually on used cars. But after numerous U.S. states went into COVID-19 lockdowns, the advantage of socially distant online sales has come into focus.







CarLotz co-founders Michael Bor (left), Will Boland (center) and Aaron Montgomery (right). 


CarLotz founders, from left, Michael Bor, Aaron Montgomery and Will Boland.

Thursday, June 3, 2021

DLocal Limited (DLO) began trading on the Nasdaq on Thur 3 June 21

DLocal Limited operates a payments platform worldwide. Its platform enables enterprise merchants to connect with consumers in emerging markets, accept payments, send payouts, and settle funds. 
The platform integrates more than 300 payment methods to expand the access to international electronic commerce. Available options include cash payment, for example, Bank Ticket in Brazil and RapiPago in Argentina, digital payment options such as UPI and NetBanking in India, and UnionPay in China, bank transfers in 13 countries as well as local cards. 
  • Sector(s): Technology
  • Industry: Software—Infrastructure
  • Full Time Employees: 365
  • Founded in 2016 
  • Headquartered in Montevideo, Uruguay
  • http://www.dlocal.com 
dLocal Limited opened at $31 after pricing 29.4 mln share IPO at $21.00 per share, above the expected range of $16.00-18.00


Sebasti├ín Kanovich, CEO 
Sebastián studied Economics, Entrepreneurship & Innovation, and Management of Technology Business at Tel Aviv University.


Kindred Biosciences (KIN) : positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus

  

 
 



 


SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from a pivotal efficacy study of KIND-030 in dogs infected by parvovirus. The primary endpoint was survival and the results showed 100% survival in the treated group versus 43% survival in the placebo group.

KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is partnered with Elanco Animal Health (NYSE: ELAN).

In this randomized, blinded, placebo-controlled study, KIND-030 was administered to dogs after they tested positive for CPV infection. The primary endpoint of the study was met. The parvovirus challenge resulted in 57% mortality rate in the control dogs compared to 0% mortality rate in the KIND-030 treated dogs. The dogs did not receive any supportive care or other treatments.

"Parvovirus is a devastating disease currently without any available treatment," said KindredBio's Chief Executive Officer, Richard Chin, M.D. "With 100% efficacy, we believe KIND-030 has the potential to revolutionize the care of these dogs. Instead of a lengthy and expensive hospitalization that is frequently ineffective and can leave the dog with permanent disabilities, the infected dogs can now be treated with a single injection without need for additional supportive care or hospitalization."

"We are excited to partner with KindredBio on this revolutionary treatment that can significantly improve the health and well-being of dogs," said Jeff Simmons, president and CEO of Elanco Animal Health. "With our significant global reach and access to veterinarians and pet owners around the world, Elanco looks forward to leveraging our capabilities and skilled team of experts to advance and commercialize this novel treatment for pets globally."

With this positive study, KIND-030 has now demonstrated efficacy in both indications being pursued: prophylactic therapy to prevent clinical signs of canine parvovirus infection, and treatment of established parvovirus infection. Results from the pivotal efficacy study for the therapeutic claim are expected to be submitted to the United States Department of Agriculture (USDA) in June, with possible approval by year-end 2021.

CPV is the most significant and contagious viral cause of enteritis in dogs, especially puppies, with mortality rates as high as 91% if untreated. There are currently no Food and Drug Administration or USDA approved treatments for CPV, nor any other available treatment. Veterinary intervention is limited to supportive care, which can cost owners up to thousands of dollars per puppy, with an average cost of $1,200.

Canine parvovirus is most often seen in puppies less than 6 months of age, but can occur in unvaccinated dogs of any age. Clinical signs often include depression, not eating, vomiting, and profuse diarrhea which is often blood tinged.1 Banfield estimates that there are approximately 250,000 parvo cases in the U.S. each year, excluding emergency hospitals, shelters, specialty hospitals, or undiagnosed cases.2

KIND-030 binds to critical portions of the virus, preventing the virus from entering into cells.

On April 28, 2021 KindredBio announced acceptance of the parvovirus antibody prophylaxis study data and approval of the efficacy indication by the USDA Center for Veterinary Biologics. The pivotal efficacy data for the prophylactic indication demonstrated that 0% of the KIND-030 treated dogs developed parvovirus infection while 100% of the placebo-control dogs developed the disease, and also showed 100% survival rate in KIND-030.

Regulatory approval and review timeline are subject to the typical risks inherent in such a process. The results of the pivotal efficacy study for the therapeutic claim stated in this press release have not been reviewed by the USDA Center for Veterinary Biologics.